A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 30, 2005

Conditions
Irritable Bowel Syndrome With ConstipationIrritable Bowel Syndrome
Interventions
DRUG

DDP733

Trial Locations (15)

T5H 4B9

Hys Medical Centre, Edmonton

V6Z 1Y6

St Paul's Hospital, Vancouver

Unknown

West Vancouver

Surrey GI Clinic, Guelph

Meadowlands Family Health Centre, Ottawa

London Road Diagnostic Clinic, Sarnia

Sarnia Institute of Clinical Research, Sarnia

B3H 2Y9

QE II Health Sciences Centre, Halifax

L8N 3Z5

McMaster University Medical Centre, Hamilton

L8N 4A6

St. Joseph's Healthcare, Hamilton

K7L 5G2

Hotel Dieu Hospital, Kingston

N6A 4V2

St. Joseph's Healthcare, London

M3H 5S4

Canadian Phase Onward Inc., Toronto

M3N 2V7

Toronto Digestive Disease Associates, Inc, Toronto

G1S 4L8

Hopital St-Sacrement, Québec

Sponsors
All Listed Sponsors
lead

Dynogen Pharmaceuticals

INDUSTRY